Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1C | Q13936 | 10/20 | 0.46 |
| ▸ | CACNA1D | Q01668 | 9/20 | 0.41 |
| ▸ | CACNA1F | O60840 | 7/20 | 0.41 |
| ▸ | CACNA1S | Q13698 | 7/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.39 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.37 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.37 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.37 |
| ▸ | SCN1A | P35498 | 2/20 | 0.37 |
| ▸ | HTR2B | P41595 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.37 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.37 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6292231 | 0.91 | ACHE (0.48) | CACNA1CCACNA1DCACNA1FCACNA1SACHE | |
| SCHEMBL7435633 | 0.90 | CACNA1C (0.36) | CACNA1CCACNA1DCACNA1FCACNA1SACHE | |
| SCHEMBL7438969 | 0.90 | CACNA1C (0.36) | CACNA1CCACNA1DCACNA1FCACNA1SACHE | |
| SCHEMBL6296626 | 0.89 | CACNA1C (0.51) | CACNA1CCACNA1DCACNA1FCACNA1SACHE | |
| SCHEMBL6760937 | 0.88 | CACNA1C (0.35) | CACNA1CCACNA1DCACNA1FCACNA1SACHE | |
| SCHEMBL6293602 | 0.87 | NR3C2 (0.41) | CACNA1CCACNA1DCACNA1FCACNA1SADORA3 | |
| SCHEMBL6296921 | 0.83 | NR3C2 (0.44) | CACNA1CCACNA1DCACNA1FCACNA1SADORA3 | |
| SCHEMBL6292206 | 0.83 | NR3C2 (0.45) | CACNA1DNR3C2ADORA2A | |
| SCHEMBL6293447 | 0.82 | CUL4A (0.38) | CACNA1CCACNA1DCACNA1FCACNA1SADORA3 | |
| SCHEMBL6296991 | 0.81 | NR3C2 (0.45) | CACNA1DADORA3NR3C2LMNAADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6977262-B2 | Dihydropyrazolopyridine compounds and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2005-12-20 | — | — | US | claimed |
| US-20040052822-A1 | Dihydropyrazolopyridine compounds and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-03-18 | — | — | US | claimed |
| EP-1355909-A2 | DIHYDROPYRAZOLOPYRIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2003-10-29 | — | — | EP | claimed |
| WO-2002062795-A2 | DIHYDROPYRAZOLOPYRIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | MITSUBISHI PHARMA CORPORATION (JP) | 2002-08-15 | — | — | WO | claimed |
| US-6977262-B2 | Dihydropyrazolopyridine compounds and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2005-12-20 | — | — | US | disclosed |
| US-20040052822-A1 | Dihydropyrazolopyridine compounds and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-03-18 | — | — | US | disclosed |
| EP-1355909-A2 | DIHYDROPYRAZOLOPYRIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2003-10-29 | — | — | EP | disclosed |
| WO-2002062795-A2 | DIHYDROPYRAZOLOPYRIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | MITSUBISHI PHARMA CORPORATION (JP) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040052822-A1 | Dihydropyrazolopyridine compounds and pharmaceutical use thereof | GSK3B, GSK3A, PYGB | CACNA1C 358/4885CACNA1D 271/4885CACNA1F 575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.